Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Raw Materials (2024 - 2025)

Iovance Biotherapeutics has reported Raw Materials over the past 2 years, most recently at $37.9 million for Q1 2025.

  • Quarterly results put Raw Materials at $37.9 million for Q1 2025, up 581.14% from a year ago — trailing twelve months through Mar 2025 was $37.9 million (up 581.14% YoY), and the annual figure for FY2024 was $27.7 million, changed.
  • Raw Materials for Q1 2025 was $37.9 million at Iovance Biotherapeutics, up from $27.7 million in the prior quarter.
  • Over the last five years, Raw Materials for IOVA hit a ceiling of $37.9 million in Q1 2025 and a floor of $5.6 million in Q1 2024.